From DCAT Value Chain Insights (VCI)
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has appointed Fred J. Frullo as vice president, regulatory affairs.
As vice president, regulatory affairs, Mr. Frullo will oversee regulatory submissions for the company's Lm-LLO cancer immunotherapy clinical programs, including ADXS-HPV, ADXS-PSA and ADXS-HER2, as well as combination studies involving complementary immunotherapy technologies. Mr. Frullo will lead the development and submission of all regulatory documents on behalf of Advaxis to the appropriate health agencies and coordinating joint submissions with Advaxis's strategic partners as warranted. In this role, Mr. Frullo will succeed Ms. Chris L. French, MBA, who will now lead the company's compliance program.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription